Interim Report January-June 2010 is published on August 3 2010 at appr. 2pm with conference call at 3pm (CET)
Västra Frölunda, Sweden, August 2 2010
Artimplant publishes Interim Report January-June 2010 on August 3 2010 at approximately 2pm (CET). The Interim Report is presented by CEO Hans Rosén and CFO Lars-Johan Cederbrant in conference call on August 3 2010 at 3pm (CET).
The presentation will be in Swedish.
Date: Tuesday August 3 2010
Time: 3pm Central European Time (CET)
Dial in numbers:
Swedish participants: +46 (0)8 506 269 04
UK participants: +44 (0)207 108 6205
US participants: +1 8666 765 870
A presentation in PDF format will be available on Artimplant's website www.artimplant.com a couple of minutes before the conference call starts.
For further information, please contact: Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com
Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54, lars-johan.cederbrant@artimplant.com
Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company's products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on August 2 2010 at 8:45 AM (CET).